PDF(2762 KB)
CXCL趋化因子在头颈部鳞状细胞癌中的表达及临床意义
武旭,达林泰,苏尼特,尚多,周兴安,德乐黑巴特尔
PDF(2762 KB)
PDF(2762 KB)
CXCL趋化因子在头颈部鳞状细胞癌中的表达及临床意义
),达林泰1,苏尼特2,尚多2,周兴安2,德乐黑巴特尔2()Effect of CXCL chemokines on the diagnosis and prognosis of head and neck quamous cell carcinoma
),Lintai Da1,Nite Su2,Duo Shang2,Xing’an Zhou2,Delehei Bateer2()目的 探讨CXCL趋化因子家族在头颈部鳞状细胞癌（HNSCC）中的表达及作为其诊断与预后标志物的价值。 方法 利用公共数据库，分析HNSCC中异常表达的CXCL因子类型以及与HNSCC患者不良预后的相关性，计算CXCL家族与免疫因子浸润的相关性。 结果 与正常组织相比，CXCL在HNSCC组织及病理分期中存在差异表达，且与HNSCC患者更长的总生存期（OS）及免疫细胞浸润密切相关；CXCL趋化因子在HNSCC中基因功能主要富集在趋化因子活性等；KEGG通路主要富集细胞因子-细胞因子受体相互作用等；CXCL家族在HNSCC中有一定的突变率。 结论 基于肿瘤生物信息学分析发现，CXCL家族在HNSCC组织中的表达水平与正常组织有差异，且其表达水平与免疫细胞浸润以及肿瘤预后具有相关性，可作为HNSCC预后标志物以及基因治疗靶点。
Objective This study investigated the expression levels of CXCL chemokines in head and neck cancer and their value as diagnostic and prognostic markers. Methods Public databases were used in the analysis of various abnormally expressed CXCL factors in head and neck cancer and their correlation with the poor prognoses of patients with head and neck cancer, and the correlation between CXCL family and immune factor infiltration was determined. Results Compared with normal tissues, CXCL is differentially expressed in head and neck squamous cell carcinoma (HNSCC) tissues and pathological stages, and it is closely related to long overall survival (OS) and immune cell infiltration in patients with HNSCC. CXCL chemokine gene function in HNSCC is mainly concentrated in chemokine activity. The KEGG pathway is mainly concentrated in cytokine-cytokine receptor interaction, and the CXCL family has a certain mutation rate in HNSCC. Conclusion Tumor bioinformatics analysis showed that the expression levels of the CXCL family in HNSCC tissues are different from those in normal tissues and correlated with immune cell infiltration and tumor prognosis, showing potential as prognostic markers for HNSCC and gene therapy targets.
趋化因子 / 生物信息学 / 头颈部鳞状细胞癌 / 预后 / 免疫浸润
chemokine / bioinformatics / squamous cell carcinoma of the head and neck / prognosis / immunoinfiltration
R739.81
| 1 | von Witzleben A, Wang C, Laban S, et al. HNSCC: tumour antigens and their targeting by immunotherapy[J]. Cells, 2020, 9(9): 2103. |
| 2 | Johnson DE, Burtness B, Leemans CR, et al. Head and neck squamous cell carcinoma[J]. Nat Rev Dis Primers, 2020, 6(1): 92. |
| 3 | Wei LY, Lee JJ, Yeh CY, et al. Reciprocal activation of cancer-associated fibroblasts and oral squamous carcinoma cells through CXCL1[J]. Oral Oncol, 2019, 88: 115-123. |
| 4 | Li YC, Wu TH, Gong SJ, et al. Analysis of the prognosis and therapeutic value of the CXC chemokine family in head and neck squamous cell carcinoma[J]. Front Oncol, 2020, 10: 570736. |
| 5 | Li HY, Wu M, Zhao X. Role of chemokine systems in cancer and inflammatory diseases[J]. MedComm, 2022, 3(2): e147. |
| 6 | 刘宇. 基于生物信息学方法筛选头颈部鳞癌枢纽基因和关联通路[D]. 长春: 吉林大学, 2022. |
| 6 | Liu Y. Screening of head and neck squamous carcinoma hub genes and associated pathways based on bioinformatics methods[D]. Changchun: Jilin University, 2022. |
| 7 | Chandrashekar DS, Karthikeyan SK, Korla PK, et al. UALCAN: an update to the integrated cancer data analysis platform[J]. Neoplasia, 2022, 25: 18-27. |
| 8 | Tomczak K, Czerwińska P, Wiznerowicz M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge[J]. Contemp Oncol, 2015, 19(1A): A68-A77. |
| 9 | Li CW, Tang ZF, Zhang WJ, et al. GEPIA2021: integrating multiple deconvolution-based analysis into GEPIA[J]. Nucleic Acids Res, 2021, 49(W1): W242-W246. |
| 10 | Nagy á, Munkácsy G, Gy?rffy B. Pancancer survi-val analysis of cancer hallmark genes[J]. Sci Rep, 2021, 11(1): 6047. |
| 11 | Li TW, Fu JX, Zeng ZX, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells[J]. Nucleic Acids Res, 2020, 48(W1): W509-W514. |
| 12 | GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016[J]. Lancet, 2017, 390(10100): 1211-1259. |
| 13 | Chen XY, Chen RP, Jin RF, et al. The role of CXCL chemokine family in the development and progression of gastric cancer[J]. Int J Clin Exp Pathol, 2020, 13(3): 484-492. |
| 14 | Yamamoto Y, Kuroda K, Sera T, et al. The clinicopathological significance of the CXCR2 ligands, CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7, and CXCL8 in gastric cancer[J]. Anticancer Res, 2019, 39(12): 6645-6652. |
| 15 | ?ukaszewicz-Zaj?c M, Mroczko B, Szmitkowski M. Chemokines and their receptors in esophageal cancer: the systematic review and future perspectives[J]. Tumour Biol, 2015, 36(8): 5707-5714. |
| 16 | 宋福勤. YAP通过调控CXCL5/CXCR2介导EGFR突变肺腺癌MDSCs迁移致T细胞增殖受抑的研究[D]. 长春: 吉林大学, 2022. |
| 16 | Song FQ. YAP mediates the migration of MDSCs by regulating CXCL5/CXCR2 resulting in the inhibition of T cell proliferation in EGFR mutant lung adenocarcinoma[D]. Changchun: Jilin University, 2022. |
| 17 | 王伊婷. CXCL9/CXCR3轴对裸鼠人舌鳞癌模型颈淋巴结转移调节作用的研究[D]. 昆明: 昆明医科大学, 2018. |
| 17 | Wang YT. The role and mechanism of CXCL9/CXCR3 axis regulating oral squamous cell carcinoma metastasis in vivo [D]. Kunming: Kunming Medical University, 2018. |
| 18 | Yorozu A, Sekiguchi S, Takasawa A, et al. CXCL12 is expressed by skeletal muscle cells in tongue oral squamous cell carcinoma[J]. Cancer Med, 2023, 12(5): 5953-5963. |
| 19 | Wang X, Zhang J, Zhou G. The CXCL11-CXCR3A axis influences the infiltration of CD274 and IDO1 in oral squamous cell carcinoma[J]. J Oral Pathol Med, 2021, 50(4): 362-370. |
| 20 | 杨惠雲. TNF相关凋亡诱导配体表达促进食管鳞癌进展的研究[D]. 郑州: 郑州大学, 2020. |
| 20 | Yang HY. Expression of TRAIL in esophageal squamous cell carcinoma promotes tumor progression[D]. Zhengzhou: Zhengzhou University, 2020. |
| 21 | Parikh A, Shin J, Faquin W, et al. Malignant cell-specific CXCL14 promotes tumor lymphocyte infiltration in oral cavity squamous cell carcinoma[J]. J Immunother Cancer, 2020, 8(2): e001048. |
| 22 | 王文涛. CXCL8-CXCR1/2在乳腺癌新辅助化疗中的变化及意义[D]. 青岛: 青岛大学, 2022. |
| 22 | Wang WT. Value and clinical significance of CXCL8-CXCR1/2 axis in neoadjuvant chemotherapy for breast cancer[D]. Qingdao: Qingdao University, 2022. |
| 23 | 毛天琴. CXCL5预测食管癌新辅助免疫治疗疗效及其与肿瘤免疫的相关性研究[D]. 成都: 电子科技大学, 2022. |
| 23 | Mao TQ. CXCL5 predict the efficacy of neoadjuvant immunotherapy for esophageal cancer and its correlation with tumor microenvironment[D]. Cheng-du: University of Electronic Science and Technology of China, 2022. |
| 24 | Liu YE, Wang D, Li ZJ, et al. Pan-cancer analysis on the role of PIK3R1 and PIK3R2 in human tumors[J]. Sci Rep, 2022, 12(1): 5924. |
/
| 〈 |
|
〉 |
AI Summary
